title: Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation.
abstract: Twenty-seven patients received pulmonary transplants during the period since we began routine use of cytomegalovirus-seronegative blood products for CMV-seronegative recipients. Preoperative serologic status of the recipient and the occurrence of cytomegalovirus infection in the postoperative period were correlated with development of obliterative bronchiolitis (OB) as diagnosed by transbronchial biopsy (TBB). Patients included 20 heart-lung and 7 double-lung recipients. OB occurred in 18 of 27 patients. All 3 CMV seronegative recipients receiving lungs from a seropositive donor and 9 of 10 CMV recipients seropositive at the time of transplantation developed OB compared with only 6 of 14 CMV seronegative patients receiving seronegative grafts (P = 0.018). CMV infection occurred in 10/27 patients, of whom 5 were asymptomatic; 90% of these patients developed OB. Donor-specific alloreactivity, based on primed lymphocyte testing (PLT) of bronchoalveolar lavage cells was found at the time of diagnosis of OB in 23 of 27 patients. A positive PLT was significantly associated with the presence of OB (P = 0.017). We conclude that preoperative seropositive status for CMV, grafting of organs from seropositive donors, and postoperative CMV infection are significant risk factors for developing OB. That OB is, in part, an immunologically mediated form of injury and represents chronic rejection is supported by the presence of donor-specific alloreactivity in BAL lymphocytes from all recipients with OB.
authors.affiliation: Department of Surgery, Medicine, University of Pittsburgh, Pennsylvania 15213.
authors.forename: R J
authors.initials: RJ
authors.lastname: Keenan
authors.forename: M E
authors.initials: ME
authors.lastname: Lega
authors.forename: J S
authors.initials: JS
authors.lastname: Dummer
authors.forename: I L
authors.initials: IL
authors.lastname: Paradis
authors.forename: J H
authors.initials: JH
authors.lastname: Dauber
authors.forename: H
authors.initials: H
authors.lastname: Rabinowich
authors.forename: S A
authors.initials: SA
authors.lastname: Yousem
authors.forename: R L
authors.initials: RL
authors.lastname: Hardesty
authors.forename: B P
authors.initials: BP
authors.lastname: Griffith
authors.forename: R J
authors.initials: RJ
authors.lastname: Duquesnoy
mesh_terms: D000914:Antibodies, Viral / Q000032:analysis; D001989:Bronchiolitis Obliterans / Q000150:complications*; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000150:complications*; D006084:Graft Rejection; D006801:Humans; D016040:Lung Transplantation / Q000276:immunology*; D012307:Risk Factors
chemical_list: D000914:Antibodies, Viral